You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Colorcon
Merck
Boehringer Ingelheim
McKesson

Last Updated: February 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Raltitrexed


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Raltitrexed?

Raltitrexed is an investigational drug.

There have been 37 clinical trials for Raltitrexed. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Neoplasm Metastasis, and Carcinoma. The leading clinical trial sponsors are Fudan University, National Cancer Institute (NCI), and Jiangsu Cancer Institute & Hospital.

There are six hundred and four US patents protecting this investigational drug and eight international patents.

Recent Clinical Trials for Raltitrexed
TitleSponsorPhase
A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal CancerJiangsu Cancer Institute & HospitalPhase 2
Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell CarcinomaNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegePhase 2
Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell CarcinomaBeijing Konruns Pharmaceutical Co., Ltd.Phase 2

See all Raltitrexed clinical trials

Clinical Trial Summary for Raltitrexed

Top disease conditions for Raltitrexed
Top clinical trial sponsors for Raltitrexed

See all Raltitrexed clinical trials

US Patents for Raltitrexed

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Raltitrexed   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Raltitrexed   Start Trial Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Raltitrexed   Start Trial Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same Duquesne University of the Holy Spirit (Pittsburgh, PA)   Start Trial
Raltitrexed   Start Trial Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   Start Trial
Raltitrexed   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Raltitrexed

Drugname Country Document Number Estimated Expiration Related US Patent
Raltitrexed World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Raltitrexed Australia 2015231053 2034-03-21   Start Trial
Raltitrexed Brazil 112016021620 2034-03-21   Start Trial
Raltitrexed Canada 2943339 2034-03-21   Start Trial
Raltitrexed China 106231900 2034-03-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Merck
Medtronic
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.